{"resourceType": "Citation", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"], "versionId": "11", "lastUpdated": "2025-10-11T21:20:49.915Z"}, "contained": [{"resourceType": "Practitioner", "id": "contributor0", "name": [{"family": "Millikan", "given": ["Randall E"]}]}, {"resourceType": "Practitioner", "id": "contributor1", "name": [{"family": "Wen", "given": ["Sijin"]}]}, {"resourceType": "Practitioner", "id": "contributor2", "name": [{"family": "Pagliaro", "given": ["Lance C"]}]}, {"resourceType": "Practitioner", "id": "contributor3", "name": [{"family": "Brown", "given": ["Melissa A"]}]}, {"resourceType": "Practitioner", "id": "contributor4", "name": [{"family": "Moomey", "given": ["Brenda"]}]}, {"resourceType": "Practitioner", "id": "contributor5", "name": [{"family": "Do", "given": ["Kim-Anh"]}]}, {"resourceType": "Practitioner", "id": "contributor6", "name": [{"family": "Logothetis", "given": ["Christopher J"]}]}, {"resourceType": "ArtifactAssessment", "id": "meshHeading0", "artifactReference": {"reference": "#", "type": "Citation"}, "content": [{"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000328", "display": "Adult", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000368", "display": "Aged", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000369", "display": "Aged, 80 and over", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000726", "display": "Androgen Antagonists", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000627", "display": "therapeutic use"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49488", "display": "Yes"}]}]}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000903", "display": "Antibiotics, Antineoplastic", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000008", "display": "administration & dosage"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49487", "display": "No"}]}]}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D018906", "display": "Antineoplastic Agents, Alkylating", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000008", "display": "administration & dosage"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49487", "display": "No"}]}]}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000972", "display": "Antineoplastic Agents, Phytogenic", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000008", "display": "administration & dosage"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49487", "display": "No"}]}]}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000971", "display": "Antineoplastic Combined Chemotherapy Protocols", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000627", "display": "therapeutic use"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49488", "display": "Yes"}]}]}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D004317", "display": "Doxorubicin", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000008", "display": "administration & dosage"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49487", "display": "No"}]}]}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D004961", "display": "Estramustine", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000008", "display": "administration & dosage"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49487", "display": "No"}]}]}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D006801", "display": "Humans", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D007654", "display": "Ketoconazole", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000008", "display": "administration & dosage"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49487", "display": "No"}]}]}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D008297", "display": "Male", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D008875", "display": "Middle Aged", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D009362", "display": "Neoplasm Metastasis", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D011471", "display": "Prostatic Neoplasms", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000188", "display": "drug therapy"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49488", "display": "Yes"}]}]}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000401", "display": "mortality"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49487", "display": "No"}]}]}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D014747", "display": "Vinblastine", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000008", "display": "administration & dosage"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49487", "display": "No"}]}]}]}]}]}], "useContext": [{"code": {"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type", "code": "fevir-platform-use", "display": "FEvIR Platform Use"}, "valueCodeableConcept": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier", "code": "medline-base", "display": "Medline Base", "userSelected": false}]}}], "classification": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type", "code": "citation-source", "display": "Citation Source"}]}, "classifier": [{"text": "MEDLINE"}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type", "code": "medline-owner", "display": "MEDLINE Citation Owner"}]}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value", "code": "NLM", "display": "National Library of Medicine, Index Section", "userSelected": false}]}]}], "statusDate": [{"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-pubmed", "display": "PubMed Pubstatus of Pubmed"}]}, "period": {"end": "2008-11-26T09:00:00.000Z"}}, {"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-medline", "display": "PubMed Pubstatus of Medline"}]}, "period": {"end": "2009-01-14T09:00:00.000Z"}}, {"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-entrez", "display": "PubMed Pubstatus of Entrez"}]}, "period": {"end": "2008-11-26T09:00:00.000Z"}}, {"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-pmc-release", "display": "PubMed Pubstatus of PMC release"}]}, "period": {"end": "2009-12-20"}}], "citedArtifact": {"identifier": [{"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "19029421"}, {"system": "https://www.ncbi.nlm.nih.gov/pmc/", "value": "PMC3864402"}, {"system": "https://doi.org", "value": "10.1200/JCO.2007.15.9830"}, {"type": {"text": "pii", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "JCO.2007.15.9830"}], "title": [{"text": "Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.", "language": {"coding": [{"system": "urn:ietf:bcp:47", "code": "en", "display": "English"}]}, "type": [{"coding": [{"system": "http://terminology.hl7.org/CodeSystem/title-type", "code": "primary", "display": "Primary title"}]}]}], "abstract": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-aritfact-abstract-type", "code": "primary-human-use", "display": "Primary human use"}]}, "text": "**PURPOSE:** We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease.\n**PATIENTS AND METHODS:** Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy.\n**RESULTS:** Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events.\n**CONCLUSION:** There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype."}], "relatesTo": [{"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/17237035/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "17237035", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/7679039/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "7679039", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 45:184-193, 2000", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/11027418/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "11027418", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/9815636/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "9815636", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Smith DC, Esper P, Strawderman M, et al: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664-1671, 1999", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/10561202/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "10561202", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53, 2001", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/11134194/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "11134194", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Millikan RE, Thall PF, Lee SJ, et al: Randomized multicenter phase II trial of two multicomponent regimens in androgen independent prostate cancer. J Clin Oncol 21:878-883, 2003", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/12610188/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "12610188", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/15470214/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "15470214", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/15470213/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "15470213", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/6337697/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "6337697", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/3523938/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "3523938", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/2213104/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "2213104", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997. (suppl)", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/9267791/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "9267791", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Janknegt RA, Boon TA, van de Beek C, et al: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. Urology 49:411-420, 1997", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/9123707/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "9123707", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/9619712/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "9619712", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 19:2157-2161, 1999", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/10472324/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "10472324", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European organization for research in cancer therapy genitourinary group trial. J Urol 162:1658-1664, 1999", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/10524892/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "10524892", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Kuriyama M, Takanhashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31:18-24, 2001", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/11256836/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "11256836", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Noguchi M, Noda Shinshi, Yoshida M, et al: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109, 2004", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/14706014/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "14706014", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Fisher LD, Belle GV: Biostatistics: A Methodology For the Health Sciences. New York, NY, John Wiley, 1993"}, {"type": "cites", "citation": "Randles RH, Wolfe DA: Introduction to the Theory of Nonparametric Statistics. New York, NY, John Wiley, 1979"}, {"type": "cites", "citation": "Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley, 1982"}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/16921051/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "16921051", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Stewart AJ, Scher HI, Chen M-H, et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/16170163/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "16170163", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/10694556/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "10694556", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Friedman J, Dunn RL, Wood D, et al: Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179:911-916, 2008", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/18207190/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "18207190", "assigner": {"display": "NLM"}}}}], "publicationForm": [{"publishedIn": {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/published-in-type", "code": "D020492", "display": "Periodical"}]}, "identifier": [{"type": {"coding": [{"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn", "code": "Electronic", "display": "Electronic"}], "text": "Electronic ISSN Type"}, "value": "1527-7755", "system": "https://portal.issn.org"}, {"type": {"text": "ISOAbbreviation", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "system": "https://www.issn.org/services/online-services/access-to-the-ltwa/", "value": "J Clin Oncol"}, {"type": {"text": "ISSN Linking", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "system": "https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/", "value": "0732-183X"}, {"type": {"text": "Medline Title Abbreviation", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "system": "https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html", "value": "J Clin Oncol"}, {"type": {"text": "NLM Unique ID", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "system": "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local", "value": "8309333"}], "title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "publisherLocation": "United States"}, "citedMedium": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-medium", "code": "internet", "display": "Internet"}]}, "volume": "26", "issue": "36", "articleDate": "2008-12-20", "pageString": "5936-42", "publicationDateText": "2008-Dec-20"}, {"citedMedium": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-medium", "code": "internet-without-issue", "display": "Internet without issue"}]}, "articleDate": "2008-11-24"}], "webLocation": [{"classifier": [{"coding": [{"system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier", "code": "abstract", "display": "Abstract"}]}], "url": "https://pubmed.ncbi.nlm.nih.gov/19029421/"}, {"url": "https://doi.org/10.1200/JCO.2007.15.9830", "classifier": [{"coding": [{"system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier", "code": "doi-based", "display": "DOI Based"}]}]}], "classification": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "publishing-model", "display": "Publishing Model", "userSelected": false}]}, "classifier": [{"coding": [{"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier", "code": "Print-Electronic", "display": "Print Electronic", "userSelected": false}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "chemical", "display": "Chemical", "userSelected": false}]}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000726", "display": "Androgen Antagonists", "userSelected": false}]}, {"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000903", "display": "Antibiotics, Antineoplastic", "userSelected": false}]}, {"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D018906", "display": "Antineoplastic Agents, Alkylating", "userSelected": false}]}, {"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000972", "display": "Antineoplastic Agents, Phytogenic", "userSelected": false}]}, {"coding": [{"system": "https://www.cas.org/support/documentation/chemical-substances", "code": "35LT29625A", "userSelected": false}, {"system": "https://www.nlm.nih.gov/mesh", "code": "D004961", "display": "Estramustine", "userSelected": false}]}, {"coding": [{"system": "https://www.cas.org/support/documentation/chemical-substances", "code": "5V9KLZ54CY", "userSelected": false}, {"system": "https://www.nlm.nih.gov/mesh", "code": "D014747", "display": "Vinblastine", "userSelected": false}]}, {"coding": [{"system": "https://www.cas.org/support/documentation/chemical-substances", "code": "80168379AG", "userSelected": false}, {"system": "https://www.nlm.nih.gov/mesh", "code": "D004317", "display": "Doxorubicin", "userSelected": false}]}, {"coding": [{"system": "https://www.cas.org/support/documentation/chemical-substances", "code": "R9400W927I", "userSelected": false}, {"system": "https://www.nlm.nih.gov/mesh", "code": "D007654", "display": "Ketoconazole", "userSelected": false}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}]}, "artifactAssessment": [{"reference": "#meshHeading0", "type": "ArtifactAssessment"}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "publication-type", "display": "Publication type"}]}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D017428", "display": "Clinical Trial, Phase III", "userSelected": false}]}, {"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D016428", "display": "Journal Article", "userSelected": false}]}, {"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D016449", "display": "Randomized Controlled Trial", "userSelected": false}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "knowledge-artifact-type", "display": "Knowledge Artifact Type", "userSelected": false}]}, "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article", "userSelected": false}]}], "artifactAssessment": [{"display": "Classifier added by Computable Publishing LLC"}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "citation-subset", "display": "Citation subset", "userSelected": false}]}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset", "code": "IM", "display": "IM", "userSelected": false}]}]}], "contributorship": {"entry": [{"contributor": {"reference": "#contributor0", "type": "Practitioner", "display": "Millikan RE"}, "forenameInitials": "RE", "affiliation": [{"display": "Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7.3462, Houston, TX 77030, USA. rmillika@mdanderson.org"}]}, {"contributor": {"reference": "#contributor1", "type": "Practitioner", "display": "Wen S"}, "forenameInitials": "S"}, {"contributor": {"reference": "#contributor2", "type": "Practitioner", "display": "Pagliaro LC"}, "forenameInitials": "LC"}, {"contributor": {"reference": "#contributor3", "type": "Practitioner", "display": "Brown MA"}, "forenameInitials": "MA"}, {"contributor": {"reference": "#contributor4", "type": "Practitioner", "display": "Moomey B"}, "forenameInitials": "B"}, {"contributor": {"reference": "#contributor5", "type": "Practitioner", "display": "Do KA"}, "forenameInitials": "KA"}, {"contributor": {"reference": "#contributor6", "type": "Practitioner", "display": "Logothetis CJ"}, "forenameInitials": "CJ"}], "complete": true}}, "approvalDate": "2009-01-13", "lastReviewDate": "2023-02-02", "currentState": [{"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "medline-medline", "display": "Medline Citation Status of Medline"}]}, {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-publication-status-ppublish", "display": "PubMed PublicationStatus of ppublish"}]}], "title": "19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net/FOI", "value": "179631", "assigner": {"display": "Computable Publishing LLC"}}, {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "19029421"}], "status": "active", "url": "https://fevir.net/resources/Citation/179631", "id": "179631", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "author": [{"name": "Computable Publishing\u00ae: MEDLINE-to-FEvIR Converter"}], "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "code": "active", "display": "Active"}]}}], "description": "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide."}